ALNY logo

ALNY
Alnylam Pharmaceuticals Inc

4,426
Mkt Cap
$42.09B
Volume
8.00
52W High
$495.55
52W Low
$205.87
PE Ratio
140.04
ALNY Fundamentals
Price
$316.09
Prev Close
$317.36
Open
$319.32
50D MA
$330.71
Beta
0.84
Avg. Volume
1.53M
EPS (Annual)
$2.33
P/B
53.02
Rev/Employee
$1.49M
$53,617.41
Loading...
Loading...
News
all
press releases
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new clinical and real-world data from its cardiovascular (CV) portfolio presented at the American...
Business Wire·16h ago
News Placeholder
More News
News Placeholder
Assenagon Asset Management S.A. Sells 54,791 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
Assenagon Asset Management S.A. trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 68.2% during the fourth quarter, according to the company in its most recent 13F...
MarketBeat·3d ago
News Placeholder
Repligen (RGEN) Down 13.5% Since Last Earnings Report: Can It Rebound?
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·5d ago
News Placeholder
SG Americas Securities LLC Buys 59,071 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
SG Americas Securities LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 185.5% in the 4th quarter, according to its most recent disclosure with the...
MarketBeat·5d ago
News Placeholder
Chardan Capital Reaffirms "Buy" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Chardan Capital reissued a "buy" rating and set a $425.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday...
MarketBeat·6d ago
News Placeholder
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given "Buy" Rating at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $510.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday...
MarketBeat·6d ago
News Placeholder
Alnylam Pharmaceuticals Touts AMVUTTRA ATTR-CM Momentum, Raises 2026 TTR Revenue Outlook
Alnylam Pharmaceuticals (NASDAQ:ALNY) used a company webinar to highlight early commercial momentum for AMVUTTRA (vutrisiran) in ATTR cardiomyopathy (ATTR-CM), outline initiatives aimed at expanding diagnosis, and discuss how management views upcoming competitive and market-access dynamics in the ca...
MarketBeat·7d ago
News Placeholder
Alnylam Advances Future of ATTR-CM Care Through Strategic Collaboration with Viz.ai and Support for the American Heart Association
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve care...
Business Wire·7d ago
News Placeholder
Congress Asset Management Co. Boosts Position in Alnylam Pharmaceuticals, Inc. $ALNY
Congress Asset Management Co. boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 126.6% in the fourth quarter, according to its most recent 13F filing with...
MarketBeat·7d ago
News Placeholder
Hudson Bay Capital Management LP Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
Hudson Bay Capital Management LP lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 38.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,411 shares of the biopharma...
MarketBeat·9d ago
<
1
2
...
>

Latest ALNY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.